RC-2: Clinical Research Core (CRC)
RC-2: Clinical Research Core (CRC)
批准号:
9277345
负责人:
Tyler J. Curiel
金额:
$9.28万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AcarboseAgingAging-Related ProcessAmericanAnimal ModelAnimalsBiological ProcessBiology of AgingBiometryCallithrix jacchus jacchusCapsicumClinicClinicalClinical InvestigatorClinical MedicineClinical PharmacologyClinical ResearchClinical TrialsConsultationsCore FacilityDisciplineDiseaseEndocrinologyEnsureFDA approvedFacultyFemaleFosteringFundingGeriatricsGerontologyGoalsHealth SciencesHumanInstitutionInterventionInvertebratesKnowledgeLeadLifeLogisticsLongevityMammalsMetforminMissionModelingMusNutraceuticalOutcomePharmaceutical PreparationsPharmacologyPhenotypePhysiologicalPhysiologyProcessRecording of previous eventsRecruitment ActivityResearchResearch PersonnelResearch Project GrantsResearch SupportResourcesRodentSafetyScienceSirolimusStructureTechnical ExpertiseTechniquesTechnologyTestingTexasTimeTrainingTranslatingTranslational ResearchTranslationsTransplant RecipientsUniversitiesWorkage relatedcancer typecareercareer developmentdata managementhealthy agingimprovedinnovationlaboratory facilitymaleneuropsychiatrynonhuman primateoncologypre-clinicalprogramsskillssuccesstherapy developmenttrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – RESOURCE CORE (RC) 2
Pharmacological aging-modulating interventions that have been validated in animal models are ready to be
translated into human clinical medicine. Among those interventions are the FDA-approved agents rapamycin,
metformin and acarbose, thus, the time has arrived to test potential aging-modulating drugs in humans. The
goal of the San Antonio Older Americans Independence Center (SA OAIC) is to advance discoveries made in
animal models (invertebrates and rodents) towards relevant human trials. To support this goal, the mission
of the Clinical Research Core [(henceforth dubbed Research Core 2 (RC2)] is to provide knowledge,
skills, techniques, logistical, and clinical research support to foster an understanding of the functional
and physiological effects of pharmacological and nutraceutical interventions on aging in older people.
RC-2 capitalizes and builds upon the rich tradition and institutional support of aging research in San Antonio,
as well as the dedicated commitment of our investigators to translational research, thereby ensuring the
success of the Core. RC2 will provide clinical research guidance to support human trials that test interventions
capable of modulating the aging process to improve and extend the healthspan and lifespan of older
Americans. The Specific Aims of the Clinical Research Core are to: 1) Assist basic and clinical investigators
in developing rigorous and appropriately powered clinical studies and trial concepts that will lead to innovative
approaches to improve healthspan and lifespan; 2) Facilitate implementation and execution of translational
human studies and clinical trials by investigators; 3) Provide expertise and coordinated access to resources
and technology in both our OAIC and facilities throughout our institution to maximize the depth of phenotypic
characterization relevant to aging in trial outcomes; 4) Provide training in clinical research for early-stage
faculty and those new to clinical research. To achieve these aims, the RC2 Core will provide research project
consultation and planning, assist with safety and regulatory compliance processes, facilitate subject
recruitment and retention, and coordinate relationships with relevant OAIC Cores and other Core facilities of
our institution. Importantly, RC2 will be critical to the OAIC’s goal of developing a clinical focus to conduct
clinical research in geriatrics with emphasis on transformative translational research to advance discoveries
from basic aging research to clinical trials and ultimately to clinical geriatrics. We will train early-career
investigators, and partner with other OAICs, institutions, and the public to advance translational aging
research. This Core will integrate other important OAIC core functions to ensure efficient trial design and
execution, including integrating studies with the OAIC Biostatistics and Data Management Core (RC3),
Research Career Development Core (RCDC), and the Pilot and Exploratory Studies Core (PESC). RC2 will
work in synchrony with the Pre-Clinical Core (RC1) so that studies conducted by both cores are compatible
and thereby facilitate translation into subsequent human trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
-
批准号:10467877
-
项目类别:
-
资助金额:$64.67万
-
财政年份:2022
-
负责人:Tyler J. Curiel
-
依托单位:
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
-
批准号:10688261
-
项目类别:
-
资助金额:$62.07万
-
财政年份:2022
-
负责人:Tyler J. Curiel
-
依托单位:
Regulation of ER-beta Signaling in Carcinogenesis
-
批准号:10092967
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2019
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
-
批准号:9788318
-
项目类别:
-
资助金额:$53.01万
-
财政年份:2018
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
-
批准号:10381324
-
项目类别:
-
资助金额:$20.98万
-
财政年份:2018
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
-
批准号:10475260
-
项目类别:
-
资助金额:$60.15万
-
财政年份:2018
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
-
批准号:10247570
-
项目类别:
-
资助金额:$56.53万
-
财政年份:2018
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
-
批准号:9926828
-
项目类别:
-
资助金额:$64.05万
-
财政年份:2017
-
负责人:Tyler J. Curiel
-
依托单位:
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
-
批准号:9307468
-
项目类别:
-
资助金额:$65.08万
-
财政年份:2017
-
负责人:Tyler J. Curiel
-
依托单位:
SENIOR LEADERSHIP
-
批准号:8709459
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2013
-
负责人:Tyler J. Curiel
-
依托单位:
Immune aspects of mTOR inhibition for cancer prevention (PQ5)
-
批准号:8538910
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
B7-H1 Signaling in Ovarian Cancer
-
批准号:8535695
-
项目类别:
-
资助金额:$29.16万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
Immune aspects of mTOR inhibition for cancer prevention (PQ5)
-
批准号:8383608
-
项目类别:
-
资助金额:$19.51万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
B7-H1 Signaling in Ovarian Cancer
-
批准号:8693606
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
B7-H1 Signaling in Ovarian Cancer
-
批准号:8871691
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
B7-H1 Signaling in Ovarian Cancer
-
批准号:8372230
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2012
-
负责人:Tyler J. Curiel
-
依托单位:
PLANNING AND EVALUATION
-
批准号:7944703
-
项目类别:
-
资助金额:$2.23万
-
财政年份:2009
-
负责人:Tyler J. Curiel
-
依托单位:
SENIOR LEADERSHIP
-
批准号:7944695
-
项目类别:
-
资助金额:$30.02万
-
财政年份:2009
-
负责人:Tyler J. Curiel
-
依托单位:
CAREER DEVELOPMENT
-
批准号:7944716
-
项目类别:
-
资助金额:$4.14万
-
财政年份:2009
-
负责人:Tyler J. Curiel
-
依托单位:
ANTIBODY
-
批准号:7944722
-
项目类别:
-
资助金额:$2.74万
-
财政年份:2009
-
负责人:Tyler J. Curiel
-
依托单位:
海外基金